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Running title: Fibromyalgia treatment effectiveness 
Abstract  
Background and aims: Fibromyalgia is a complex condition characterised by widespread pain, sleep 
disturbance, fatigue and cognitive impairment, with a global mean prevalence estimated at 2.7%. 
There are inconsistencies in guidelines on the treatment of fibromyalgia leading to dissatisfaction 
from patients and healthcare professionals. This study investigated patient-reported outcomes of 
pharmacological and non-pharmacological treatment usage and effectiveness with an assessment of 
acceptability.  
Methods: Nine hundred and forty-one participants completed a self-administered anonymous 
questionnaire giving quantitative data of demographics, treatment usage and treatment outcomes. 
Participant-reported effectiveness and side effects were compared in the following treatment classes: 
analgesics, antidepressants, gabapentinoids, gastrointestinal treatments, activity interventions, dietary-
based treatments, and psychological, physical and alternative therapies. Participants also reported 
whether they knew about or had tried different treatments. 
Results: The results from the online survey indicated that the range of mean effectiveness ratings 
were similar for pharmacological and non-pharmacological treatments, whereas non-pharmacological 
treatments had lower side effects ratings and higher acceptability relative to pharmacological 
treatments. Participants were not aware of some treatment options. 
Conclusions: The results show lower side effects ratings and higher acceptability for non-
pharmacological treatments compared to pharmacological treatments despite similar effectiveness 
ratings. 
Implications: This article presents results from a large online survey on fibromyalgia patient 
perspectives of pharmacological and non-pharmacological treatments. Results will inform healthcare 
professionals and patients about optimal treatments based on ratings of effectiveness, side effects and 
acceptability that are tailored to patient symptom profiles. Some participants were unaware of 
treatment options highlighting the importance of patient education allowing collaboration between 
patients and healthcare professionals to find optimal treatments. 
 
Key words: Fibromyalgia, patients’ perspective, online survey, pharmacological treatments, non-
pharmacological treatments 
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Introduction 
Fibromyalgia is a complex condition characterised by widespread pain, sleep disturbance, fatigue and 
cognitive impairment [1,2]
 
with a global mean prevalence estimated at 2.7% [3]. Fibromyalgia is 
often comorbid with mood and anxiety disorders impacting on social, family and working identities 
[4-7]. 
 
Treatment interventions include pharmacological, psychological, exercise and alternative therapy 
approaches [8-11]. Evidence for the effectiveness of these interventions in reducing symptoms is 
varied and inconsistent, with no treatment approach being universally accepted [12], possibly due to 
the heterogeneity of the condition and proposal of subgroups [13,14]. Current pharmacological 
treatment has modest efficacy, high incidence of adverse effects and poor adherence [15,16]. 
 
There are inconsistencies in guidelines on the treatment of fibromyalgia [17-19].
 
Previous EULAR 
guidelines [20]
 
gave the highest recommendation to pharmacological treatments whereas EULAR 
revised guidelines [21]
 
suggested that the first treatment should be non-pharmacological and strongly 
recommended exercise. Treatment should be individualised based on the patient symptom profile and 
need, which may include psychological therapy (e.g. cognitive behavioural therapy (CBT), 
mindfulness), physical therapy (e.g. acupuncture or hydrotherapy) and pharmacotherapy (e.g. 
duloxetine, pregabalin, tramadol or amitriptyline) [21-23]. Multimodal treatments were recommended 
in people with severe disability. There are inconsistencies between the EULAR guidelines and 
previous guidelines from Germany [23], Canada [24] and Israel [25].
 
The Canadian and Israeli 
guidelines strongly recommended serotonin noradrenaline reuptake inhibitors (SNRIs) and 
anticonvulsants, although these were weakly recommended in EULAR guidelines. Revised EULAR 
guidelines did not recommend non-steroidal anti-inflammatory drugs (NSAID), steroidal anti-
inflammatory drugs, monoamine oxidase inhibitors or selective serotonin reuptake inhibitors due to 
lack of efficacy and strongly discouraged the use of corticosteroids, strong opioids, growth hormone 
and sodium oxybate [21]. Revised German guidelines recommend multimodal therapy combining 
exercise (endurance, strength or flexibility training) and psychotherapeutic therapy (patient training or 
cognitive behavioural therapy) [26]. Comparing guidelines shows inconsistencies in terms of the 
importance given to pharmacological versus non-pharmacological therapies. 
 
Dissatisfaction from patients and health professionals with treatment management [27, 28]
 
highlights 
the importance of investigating patients’ perceptions of treatment efficacy and adverse side effects. 
Pain reduction is the main criterion for pharmacological regulation, although fibromyalgia is also 
associated with other symptom domains of pain, sleep disturbance, affective symptoms, fatigue, 
cognitive impairment and functional deficit [29, 30]. This study involved the investigation of patient-
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reported outcomes of pharmacological and non-pharmacological treatment usage and effectiveness, 
with an assessment of acceptability of therapeutic approaches because pharmacological and non-
pharmacological treatments may differ in tolerability [29]. While previous research has reported 
patient-perceived efficacy of treatments [31], the present study will extend this by assessing self-
report effectiveness, including which symptoms are relieved, and side effects for a range of 
treatments. Randomised control trials in fibromyalgia have been criticised due to limited external 
validity because participants with comorbidities may be excluded [32] so this study employed a large 
online survey to ascertain patient reported outcomes. 
 
Method 
Questionnaire development 
The questionnaire was developed from the outcomes of a pilot study of individual qualitative 
interviews [28] and a review of existing literature. A self-administered anonymous questionnaire was 
conducted using Qualtrics [33] that asked participants to provide quantitative and qualitative data 
about a variety of areas including demographics, condition profile, condition impact, treatment usage 
and treatment outcomes. Thus, the structure of the survey included items related to the physical and 
psychological symptoms and management. Members of the fibromyalgia research team at Sheffield 
Hallam University reviewed the structure, questions and ease of completion to ensure the survey was 
comprehensive, balanced and user-friendly. This paper focuses on the quantitative data on treatment 
outcomes from the survey.  
 
This research project received ethical approval from the Sheffield Hallam University Research Ethics 
Committee.  
 
Recruitment and data collection 
Fibromyalgia charities and networks, and affiliated member support groups within the UK posted the 
survey online with additional notification through emails and on Facebook pages from January 2016 
to April 2016. To take part in the survey, participants were required to be over 18 years of age and to 
have received an official diagnosis of fibromyalgia. Participants were informed about the voluntary 
and anonymous nature of the survey, the information that would be collected and the expected time 
for survey completion. Completion and submission of the survey was taken as implied consent and 
participants were free to withdraw their data up to two weeks after participation. To avoid potential 
fatigue, participants had the option of taking breaks during survey completion. Average completion 
time was 1 hour 15 minutes. 
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Measures 
The first section asked participants to provide demographic information including age, gender, 
employment status, relationship status and qualifications. The next section focused on treatment-
specific information with participants asked to state whether they had tried, had not tried, did not 
know about or would not try identified treatment options. The survey included a range of commonly 
used pharmacological and non-pharmacological treatments. Participants were asked to rate their 
personal experience of tried treatments on the basis of the effectiveness and severity of side effects on 
11-point Likert scales (effectiveness of treatment 0 = not effective to 10 = very effective and side 
effects 0 = none to 10 = terrible). Further questions required participants to select one symptom (from 
a choice of nerve pain, fatigue, brain fog, muscular pain, bone/joint pain, anxiety, depression, irritable 
bowel syndrome (IBS)/gastric issues) that the treatment was most effective in reducing and select 
which side effect (from a choice of feeling nauseous, feeling tired, feeling disorientated, made pain 
worse, worse mood, weight gain, dry mouth, anxiety, incontinence, constipation, pain during 
treatment or none) gave the worst experience.  
 
Participants completed the ‘Sensory Reactivity’ and ‘Pain and Consequences’ subscales from the 
Comprehensive Rating Scale for Fibromyalgia Symptomatology (CRSFS) [34]. Participants rated 
whether they had experienced a range of symptoms never, once, on several days, more than half of 
days or almost every day over the previous 2 weeks causing discomfort or affecting daily life. Sensory 
reactivity items focused on joint discomfort, pain, stiffness, sensation changes, night cramps and 
tingling sensations. Pain and consequences items assessed sleep quality, neck and back pain, headache 
and physical and general tiredness and were scored as follows: never/once (0), several days (1), more 
than half of the days (2) and almost every day (3). Scores of the subscales were totalled giving a 
possible range of 0-54 for symptoms of sensory reactivity and 0-63 for symptoms of pain and 
consequences. Higher scores indicate greater sensory reactivity and pain and consequences. The 
CRSFS Sensory Reactivity (Cronbach’s alpha = 0.89) and Pain and Consequences (Cronbach’s Alpha 
= 0.87) subscales had good reliability. 
 
The Hospital Anxiety and Depression Scale (HADS) [35] assessed state anxiety and depression with 
seven items scored between zero and 3 on each subscale. ‘I feel tense or wound up’ is an example 
from the anxiety subscale and ‘I feel cheerful’ is an example from the depression subscale. Scores of 
0 to 7 were categorised as normal, 8 to 10 as mild, 11 to 15 as moderate and 16 to 21 as severe [35]. 
The Anxiety (Cronbach’s Alpha = 0.84) and Depression (Cronbach’s Alpha = 0.83) subscales had 
good reliability. 
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Analyses 
Summary statistics were calculated as means and standard deviations (SD) for continuous variables 
and frequency (%) for categorical variables. Data were ranked by decreasing effectiveness scores. The 
range of effectiveness and side effects ratings for pharmacological and non-pharmacological 
treatments were compared by Mann Whitney U test with a significance level of 0.05. A treatment 
acceptance ratio was calculated for each intervention from the mean effectiveness value and the mean 
side effects value. The range of acceptance ratios for the pharmacological and non-pharmacological 
treatments were compared by Mann Whitney U test with a significance level of 0.05. Mann Whitney 
U tests were used because these analyses were based on ranked data. 
 
The participant-reported outcomes were evaluated within the different classes of treatments to identify 
the preferred therapies. Between group ANOVAs comparing the effectiveness and severity of side 
effects were reported for treatment groups with three or more treatments. Hochberg’s GT2 post hoc 
tests were reported because these tests are recommended when sample sizes are different [36] and 
there is some variation in number of participants who tried different treatments. t-tests are reported 
when there were two treatment types in a group. The significance level was set at 0.05. Parametric 
analyses were conducted because box plots and skewness statistics indicated that the data were 
normally distributed. 
 
Results 
Participant demographics  
Nine hundred and forty-one participants started the survey with seventy six per cent of participants 
completing 50% or more of the survey. t-tests were conducted to compare participants who had 
completed the entire survey with participants who had not completed the entire survey in terms of age, 
CRSFS sensory reactivity, CRSFS Pain and Consequences and HADS Anxiety and Depression 
scores. Participants who completed the whole survey were significantly older (M = 48.83, SD = 
12.24) than participants who did not complete the whole survey (M = 46.57, SD = 11.84, t (936) = 
2.88, p = 0.004). Participants who finished the survey reported significantly lower CRSFS sensory 
reactivity (M = 34.99, SD = 10.63) relative to participants who did not finish the survey (M = 36.78, 
SD = 10.27, t (906) = 2.58, p = 0.010). Participants who completed the survey reported significantly 
lower depression scores (M = 10.29, SD = 4.35) compared to those who did not complete the whole 
survey (M = 10.97, SD = 4.26, t (931) = 2.42, p = 0.016). There were no differences in terms of 
CRSFS Pain and Consequences (t (890) = 1.62, p = 0.106) or Anxiety (t (931) = 2.42, p = 0.051). 
 
Participant demographic data are presented in Table 1. The demographic characteristics indicated that 
the respondents were 94.8% white females with a mean age of 47 years. Fifty-two per cent of 
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participants were married or in a partnership, 40.1% were in employment and 30.5% had a university 
education. The time since diagnosis ranged from 0 to 37 years with a mean of 5 years.  
[Insert Table 1 approximately here]. 
 
Use and knowledge of treatments 
Participant engagement with UK-licensed pharmacological and non-pharmacological treatments are 
presented in Tables 2 and 3. Six of the considered treatments had been tried by 75% or more of the 
participants: paracetamol (92.5%), heat pad/hot water bottle (81.8%), codeine (79.3%), ibuprofen 
(77.6%), walking/running (76.1%) and amitriptyline (75.9%). Only five of the treatments were 
identified by greater than 20% of participants as "would not try": cycling (55%), gym exercise 
(39.5%), steroid tablets (28.6%), morphine (28.3%) and fluoxetine (24.4%). The participants were 
aware of the majority of the non-pharmacological treatments considered, other than colpermine which 
45.3% of participants did not know (Table 3). In contrast, Table 2 shows that a third of the 
pharmacological treatments considered were not known by greater than 50% of participants: 
Audmonal (alverine) (73%), nefopam (72.2%), nortriptyline (58.1%), fentanyl/Butrans 
(buprenorphine) patches (57.2%), sertraline (55.3%), ranitidine (54.6%) and duloxetine (51.7%).  
[Insert Tables 2 and 3 approximately here]. 
 
 
Effectiveness and side effects of treatments 
Tables 4 and 5 show the mean effectiveness and side effects ratings of pharmacological and non-
pharmacological treatments. The range of mean effectiveness scores, rated on an 11-point Likert scale 
for pharmacological (2.54–6.85) and non-pharmacological treatments (3.54–6.33) were similar (U = 
197.5, p > 0.05) (Tables 4 and 5). The predominant symptoms identified as gaining greatest relief, 
pain, depression and anxiety, again were similar within both types of treatment. In contrast, a 
significantly lower range of mean side effects scores was reported for non-pharmacological treatments 
(0.62–6.13) relative to pharmacological treatments (1.17–6.34) (U = 132, p = 0.027). The 
predominant side effects identified with pharmacological treatments were nausea and disorientation, 
whilst with non-pharmacological treatments were pain and tiredness (Tables 4 and 5). 
[Insert Tables 4 and 5 near here]. 
 
Treatment classes  
Analgesics 
Muscular pain was the most frequently reported symptom alleviated by analgesic treatments (Table 
4). There was a significant effect of analgesic type on effectiveness (F (3, 1665) = 38.17, p < 0.001) 
and side effects (F (3, 1661) = 115.34, p < 0.001). A comparison of the analgesics paracetamol and 
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nefopam, which received the lowest mean effectiveness scores (2.54 and 3.35, respectively), indicated 
there was no difference in effectiveness (t(732) = 1.76, p = 0.383), however the participant-rated side 
effects of nefopam were significantly higher than those of paracetamol (t(732) = 7.12, p < 0.001). 
Although 33.8% of participants who tried paracetamol reported it relieved muscular pain, 42% of 
participants reported that it did not alleviate any symptoms. Naproxen was rated as significantly more 
effective compared to ibuprofen (t(933) = 3.35, p = 0.005). There were, however, significantly higher 
scores for side effects for naproxen (t(931) = 5.17, p < 0.001) relative to ibuprofen.  
 
For opioid analgesics, there was a significant main effect on effectiveness (F(3, 1342) = 49.11, p < 
0.001) with morphine  rated by participants as significantly more effective than codeine (t(798) = 
12.05, p < 0.001), tramadol (t(606) = 7.91, p < 0.001) or fentanyl (t(288) = 6.72, p < 0.001). Further, 
tramadol (t(288) = 5.10, p < 0.001), but not fentanyl, was significantly more effective than codeine. 
There was a significant main effect for side effects of opioid analgesics (F(3, 1319) = 15.49, p < 
0.001) with the side effects scores significantly greater for tramadol compared to codeine (t(1041) = 
5.33, p < 0.001) and fentanyl (t(556) = 5.58, p < 0.001). In addition, participants reported greater 
scores for side effects for morphine relative to fentanyl (t(278) = 3.89, p = 0.001).  
 
Antidepressants 
Participants reported that the symptom most frequently alleviated following treatment with 
amitriptyline or nortriptyline was pain; however, depression was the most reported symptom to be 
reduced with the other antidepressants citalopram, sertraline, duloxetine and fluoxetine (Table 4). 
There was a significant main effect of effectiveness for antidepressant type (F(5, 1285) = 3.06, p = 
0.009). Sertraline was the only antidepressant reported as more effective than amitriptyline (t(671) = 
3.18, p = 0.022). There was a significant main effect of side effects for antidepressant type (F(5, 
1283) = 6.33, p < 0.001). Participants reported significantly greater side effects scores for 
amitriptyline compared to citalopram (t(758) = 3.36, p = 0.012) and sertraline (t(675) = 4.67, p < 
0.001), while nortriptyline had significantly greater reported side effects scores relative to sertraline 
(t(186) = 2.94, p = 0.049).  
 
Gabapentinoids  
Pain reduction was the most frequently reported effectiveness outcome associated with pregabalin and 
gabapentin (Table 4). The scores for effectiveness (t(617) = 0.419, p = 0.675) and side effects (t(631) 
= 0.886, p = 0.376) for gabapentin and pregabalin were similar. 
 
Gastrointestinal treatments 
Eighty-four per cent or greater of participants reported that gastrointestinal treatments suppressed 
gastrointestinal disturbance and/or IBS (Table 4). There was a significant effect of gastrointestinal 
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treatment on effectiveness (F (3, 668) = 23.92, p < 0.001) with omeprazole rated as significantly more 
effective than ranitidine (t(480) = 4.72, p < 0.001) or audmonal (t(432) = 5.30, p < 0.001). The ratings 
of the side effects associated with the gastrointestinal treatments studied did not achieve significance 
(F(3, 688) = 0.38, p = 0.765). 
 
Activity interventions 
Muscular pain was identified as the symptom most alleviated by all activity type interventions, except 
walking/running, which was more associated with enhancing mood (Table 5). The most frequently 
reported side effect, however, with all activity interventions was an enhancement of pain. There was a 
significant main effect of effectiveness for activity type (F(4, 1550) = 4.41, p = 0.002) with swimming 
(t(643) = 3.67, p = 0.002) and walking/running (t(795) = 3.67, p = 0.003) rated as significantly more 
effective than controlled/graded exercise plans (Table 5). There was a significant main effect of side 
effects for activity type (F(4, 1650) = 10.79, p < 0.001). Compared to swimming, participants rated 
significantly greater side effect scores for gym exercise (t (643) = 6.08, p < 0.001), cycling (t(556) = 
3.81, p = 0.001), walking/running (t(951) = 4.73, p < 0.001) and controlled/graded exercise plan 
(t(679) = 3.77, p = 0.002).  
 
Dietary-based treatments  
The dietary changes that participants reported included healthy eating, gluten free, dairy free, eating 
more fruit and vegetables, Paleo diet and eating less sugar. Supplements that participants reported 
taking included multivitamins, vitamin B, vitamin C, vitamin D, magnesium and glucosamine. 
Participants associated dietary-based treatments with reduced gastrointestinal symptoms and reduced 
fatigue (Table 5). Dietary changes were rated as significantly more effective compared to vitamin 
supplements (t(718) = 5.67, p < 0.001) (Table 5). The majority of participants (up to 88%) who had 
used dietary-based approaches to treatment had experienced no undesirable side effects.    
 
Psychological therapies 
Participants reported engaging with a range of psychological therapies including talking therapy, 
integrative psychotherapy, person centred, eye movement desensitisation and reprocessing, 
hypnotherapy and Mickel therapy, a talking therapy for chronic health conditions. Psychological 
therapies were most frequently associated with enhancement of mood (Table 5). There was a 
significant effect of type of psychological therapy on effectiveness (F(4, 1096) = 16.68, p < 0.001) 
with mindfulness (t(432) = 3.75, p = 0.002), counselling (t(458) = 3.75, p = 0.002) and 
meditation/relaxation (t(507) = 4.63, p < 0.001) all rated as significantly more effective than 
Cognitive Behavioural Therapy (CBT) (Table 5). Participants reported a low frequency of undesirable 
side effects with psychological therapies (less than 13% of participants for any effect). There was a 
significant effect for type of psychological therapy for side effects (F(4, 1152) = 29.99, p < 0.001) 
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with the ratings of side effects for counselling and CBT being significantly greater relative to 
mindfulness (t(410) = 6.09, p < 0.001 and t(439) = 3.89, p = 0.001, respectively) and 
meditation/relaxation (t(508) = 7.24, p < 0.001 and t(537) = 4.84, p < 0.001, respectively).  
 
Physical therapies 
The symptom that was most frequently reported to be alleviated by physical therapies was muscular 
pain (Table 5). On the basis of participant ratings, the three non-pharmacological treatments identified 
as most effective were hydrotherapy, heat pad/hot water bottle and massage (Table 5). Hydrotherapy 
and heat pad/hot water bottle treatments were rated as significantly more effective than physiotherapy 
(t(500) = 9.58, p < 0.001 and t(920) = 12.84, p < 0.001, respectively), acupuncture (t(396) = 5.89, p < 
0.001 and t(816) = 7.05, p < 0.001, respectively), or transcutaneous electrical nerve stimulation 
(TENS) (t(419) = 7.37, p < 0.001 and t(839) = 9.15, p < 0.001, respectively) (Table 5). Further, 
participants reported that massage was significantly more effective than physiotherapy (t(677) = 
11.00, p < 0.001) or TENS (t(639) = 8.01, p < 0.001).  
 
Enhancement or inducement of pain during physical therapies, however, was the most frequently 
reported side effect (Table 5). The side effects score associated with heat pad/hot water bottle 
treatment was significantly lower than that reported for acupuncture (t(876) = 7.30, p < 0.001), 
massage (t(939) = 15.38, p < 0.001), physiotherapy (t(991) = 23.94, p < 0.001), TENS (t(913) = 7.28, 
p < 0.001) and hydrotherapy (t(764) = 8.95, p < 0.001).  Hydrotherapy and massage had significantly 
lower reported side effects scores than physiotherapy (t(515) = 7.63, p < 0.001 and t(690) = 6.71, p < 
0.001, respectively).  
 
Alternative therapies 
Whilst the effectiveness of aromatherapy, colpermin (peppermint oil) and distraction therapy through 
hobbies were similar (F(2, 729) = 2.86, p = 0.058), there was a significant main effect of side effects 
(F(2, 785) = 7.07, p = 0.001) with significantly fewer side effects reported for aromatherapy 
compared to distraction through hobbies (t(661) = 3.64, p = 0.001).  
 
Participant acceptability of treatments 
The relationship between the effectiveness of a treatment and the side effects was determined as an 
assessment of participant-rated acceptance. An acceptability ratio greater than 1 indicated that the 
benefits outweighed limitations as assessed from the participants’ perspective. The acceptability ratio 
for pharmacological treatments range was 0.67–3.92 with nine of 21 interventions giving a value 
greater than 1 (Table 6). For non-pharmacological treatments, the acceptability ratio range was 0.60–
9.65 with 15 of 21 interventions giving a value of greater than 1 (Table 7). The acceptability ratio 
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range for non-pharmacological treatments was significantly higher than that for pharmacological 
treatments (U = 141.5, p = 0.048). 
 
Discussion  
This study reported results from a large online survey about patients’ ratings of effectiveness and side 
effects of treatments for fibromyalgia. Findings indicated similar effectiveness ratings for 
pharmacological and non-pharmacological treatments. There were, however, significantly lower mean 
side effects ratings and a higher acceptability ratio for non-pharmacological treatments compared to 
pharmacological treatments. There is no universally accepted treatment approach for fibromyalgia 
[12]
 
with inconsistencies between treatment guidelines [18]. By analysing the effectiveness and side 
effects ratings from a patient perspective within a range of treatment approaches, this will inform 
healthcare professionals and patients about optimal treatments based on ratings of acceptability. An 
individualised treatment approach for fibromyalgia based on patient symptom profile is recommended 
[21]. The survey data demonstrated the effects of various treatment approaches on different symptoms 
of fibromyalgia. Such data will allow for tailored, individualised treatment approaches. 
 
Previous research 
Survey results supported a previous fibromyalgia survey that found non-pharmacological treatments 
were more effective at symptom relief than pharmacological treatments with worst side effects 
reported for strong opioids and gabapentinoids [32]. The current survey results showed limited 
effectiveness of pharmacological treatments including analgesics, gabapentinoids and antidepressants, 
supporting the EULAR guidelines that suggested weak evidence for the efficacy of pharmacological 
treatments [21].
 
A review of pharmacological therapies in fibromyalgia highlighted the importance of 
tailoring drug therapy based on key symptoms other than pain, psychological and physical 
comorbidities and the importance of problematic side effects to the individual e.g. weight gain [15]. 
Research suggests there are subgroups of fibromyalgia symptoms based on personality with cluster 1 
characterised by higher neuroticism and lower extraversion, remaining more anxious and depressed 
during treatment, compared to cluster 2 [37]. The clusters should be included in the design of future 
treatments and clinicians should be aware of cluster types during patient interaction. An alternative 
subgroup categorisation in fibromyalgia patients is based on 1) functional, 2) dysfunctional and 3) 
highly dysfunctional and distressed profiles [13]. 
 
Activity  
The EULAR and Canadian guidelines strongly recommended exercise because of pain reduction, 
wellbeing and low cost [21, 24]. Self-report data from the survey, however, showed acceptability for 
activity types (gym exercise, cycling, walking/running, swimming and exercise plans) was less than 1 
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indicating that undesirable effects outweighed effectiveness. It is possible that benefits of activity are 
only evident when participants take part in regular activity. More research is needed to determine the 
recommended intensity and frequency of activity for benefits of symptom relief to be achieved [38]. 
High attrition rates and participants not adhering to activity, however, are problems associated with 
activity interventions [39]. Comparing the different types of activity included in the survey, 
swimming was more effective than exercise plans and participants reported lower side effects 
compared to gym exercise, cycling, walking/running and exercise plans. Swimming may be beneficial 
to pain because hydrostatic pressure and buoyancy may reduce muscle spasm and increase the pain 
threshold of nerve endings resulting in decreased pain sensation [40].  
 
Physiotherapy 
Enhanced pain was a commonly reported side effect for activity and physiotherapy. A systematic 
review identified increased pain during activity as a barrier to physiotherapy adherence in 
musculoskeletal outpatients, together with low levels of physical activity at the start of therapy, low 
adherence to exercise during therapy, low self-efficacy, depression, anxiety, helplessness, poor social 
support and greater perceived barriers to exercise [41]. Simple analgesics, heat or ice with passive 
physiotherapy (e.g. acupuncture or manual therapy) may reduce pain allowing the use of more active 
treatments [42]. Physiotherapists should aim to change maladaptive pain beliefs when patients believe 
that pain experienced during physiotherapy is harmful [41]. Patients with fibromyalgia would benefit 
from more specialist physiotherapists and psychologists in the healthcare system and integrated 
interdisciplinary care [43]. 
 
Dietary changes 
Participants reported that diet change helped to alleviate gastric symptoms and had low side effects. 
Research shows that for subgroups of patients, dietary changes, such as gluten-free diet, were 
associated with improvements in fibromyalgia symptoms [44]. Noxious macromolecules may trigger 
release of mast cell mediators and immune system activation, resulting in pain [45]
 
so that reduction 
in noxious macromolecules through diet change may improve pain symptoms. Dietary changes are 
not included in current guidelines, although it has been suggested that nutrition has the potential to be 
recommended as an effective therapy following more research [46].
 
Fibromyalgia treatment should 
include specific dietary interventions, weight loss strategies, nutritional education and tailored 
nutritional supplements [47]. 
 
Psychological therapy 
The results of this survey showed that mindfulness was more effective than CBT and pain 
management courses with 33% of participants who had tried mindfulness reporting it alleviated 
anxiety. This contrasts with the Canadian guidelines that highly recommend CBT [24]. One meta-
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analysis reported small short-term effects of mindfulness-based stress reduction on pain and quality of 
life in people with fibromyalgia, although there was only a weak recommendation due to the small 
number of studies and low-quality evidence [48]. Developing coping skills is important in treating 
fibromyalgia [24] and mindfulness encourages an accepting pain coping style, rather than reducing 
pain [48]. Twenty-six per cent of participants in the current sample reported they did not know about 
mindfulness as a treatment for fibromyalgia indicating that mindfulness should be more widely 
recommended with online resources and courses advertised to people with fibromyalgia.  
 
Heat pad treatment 
Heat pad treatment had the highest acceptability ratio with high effectiveness and low side effects 
reported. Heat treatment (i.e. thermotherapy) is a very old method of pain relief [49]. There is 
evidence that participants who received whole-body hyperthermia showed a significant reduction in 
pain compared to a control group [50]. In the current survey, 74% of participants who had tried a heat 
pad reported that it alleviated muscular pain and 94% reported no side effects. This supports the 
findings of a previous online survey [31]
 
that reported heat pad was the fourth most effective 
treatment in an internet survey of participants with fibromyalgia (following prescription sleep 
medication, prescription pain medication and resting). Eleven per cent of participants reported they 
had not tried this treatment and only 3.8% of participants reported they would not try using a heat pad. 
Healthcare professionals should discuss using heat pads with people who have fibromyalgia because 
this treatment was found to be highly acceptable, easy to administer and inexpensive. While the exact 
mechanism of heat and pain reduction is unclear [51], sedative effects on sensory nerve endings [52]
 
and capillary dilation [53] are possible explanations.  
 
Distraction therapy 
Distraction therapy through hobbies was another treatment that participants rated as effective with a 
low number of side effects. An explanation for this finding is that attention is diverted away from 
symptoms. A systematic review of distraction-based treatments noted that it is important to examine 
predictors of treatment outcomes, including personality, so that pain management strategies can be 
individualised to the patient [54].  
 
Strengths and limitations 
Strengths of this study are the relatively large community participant sample exhibiting profiles 
typically expected of patients with fibromyalgia and the patients’ perspective reflecting a real-world 
setting. In addition, the survey included effectiveness and side effects of treatments, important factors 
in treatment adherence and acceptance. Furthermore, the survey included a range of treatments: 
pharmacological, activity, psychological, physical and alternative therapies. Strengths and limitations 
inherent to online survey research must also be noted and considered in the interpretation of the 
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results. Strengths include access to specific populations, the collection of a large amount of data 
quickly and low cost, although self-selection bias is a potential limitation because some individuals 
may be more likely to respond than others [55].  
 
Limitations of the sample should be acknowledged. For example, the sample contained a lower 
percentage of participants who had a university education (30.5%) compared to 40% in the general 
population [56], possibly indicating sampling bias. Furthermore, participants who completed the 
entire survey were significantly older and reported significantly lower sensory reactivity and 
depression scores compared to participants who did not complete all the survey. Therefore the current 
sample may not accurately reflect the wider demographic of fibromyalgia patients. The survey was 
advertised by fibromyalgia organisations and on social media, thereby participants had Internet access 
and an active interest in the topic. The use of patient advocacy groups and websites to access 
respondents could lead to over-representation by individuals seeking support and fellowship because 
of experienced problems. Although participants were required to have received an official diagnosis 
of fibromyalgia, the diagnostic method was not determined and could not be confirmed, and 
fibromyalgia severity was not established. A further limitation was that participants were not asked 
about current treatments and the past tense emphasis of the questions (e.g. have tried) may have led to 
recall bias of over- or underestimation of patient reports. It is possible that participants were using 
more than one treatment, following guidelines that suggest a multimodal treatment approach. The 
survey did not include dose, intensity or method of administration of treatments and these may have 
affected effectiveness and side effects ratings. Therefore, survey results show patients’ perspectives of 
effects and side effects of the doses and duration of drug treatments commonly used for fibromyalgia.   
 
In conclusion, the main survey findings were that participants reported lower mean side effects and 
higher mean acceptability, although mean effectiveness was similar, for non-pharmacological 
treatments compared to pharmacological treatments. Participants were not aware of some treatment 
possibilities indicating that patient education is important for highlighting the range of available 
treatments allowing optimal informed treatment decision making with their healthcare professional.  
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Table 1. Demographics of the respondent population (n = 941). Data are expressed and ranked as 
percentage of responses for each category, except age and time since diagnosis which is presented as 
mean with standard deviation. 
Characteristics % (number of participants) 
Gender 
Female, n (%) 94.8 (892) 
Male, n  4.8 (45) 
Not reported, n (%) 0.3 (3) 
Mixed gender, n (%) 0.1 (1) 
Age, years (SD) 47.7 (12.1) 
Time since diagnosis, years (SD) 5.0 (5.5) 
Ethnicity (%) 
White 95.9 (902) 
Mixed-race 1.6 (15) 
Asian 1.0 (9) 
Black 0.6 (6) 
Other 0.5 (5) 
Not reported 0.4 (4) 
Marital status  
Married or civil partnership 52.3 (492) 
Single 13.9 (131) 
Co-habiting 13.6 (128) 
Divorced 13.6 (128) 
Separated 3.9 (37) 
Widowed 2.1 (20) 
Not reported 0.5 (5) 
Employment status 
Unemployed due to FM 38.9 (366) 
Working full-time 21.8 (205) 
Working part-time 18.3 (172) 
Retired 10.0 (94) 
Homemaker 5.7 (54) 
Student 3.0 (28) 
Unemployed reason unknown 1.8 (17) 
Not reported 0.5 (5) 
Areas of employment 
Healthcare 24.1 (227) 
Administration 11.8 (111) 
Teaching & education 10.4 (98) 
Qualification 
GCSE/O-Level 59.4 (559) 
Vocational 29.6 (279) 
A-Level 26.2 (247) 
Graduate 24.3 (229) 
Post-graduate 6.2 (58) 
None 5.8 (55) 
Apprenticeship 2.6 (24) 
Non-UK 2.1 (20) 
Note. General Certificate of Secondary School (GCSE) qualifications are traditionally completed in the UK at age 
16. GCSEs replaced Ordinary Levels (O-Levels) in 1988. Advanced Levels (A-Levels) are traditionally studied 
between ages 16 and 18.   
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Table 2. Participant engagement with pharmacological treatments. NSAID = non-steroidal anti-
inflammatory drug, SNRI = serotonin noradrenaline reuptake inhibitor, SSRI = selective serotonin 
reuptake inhibitor, TCA = tricyclic antidepressant.  
Drug Class of drug Have tried this 
treatment % 
Have not tried 
this treatment % 
Would not try 
% 
Don’t know 
this treatment 
% 
Paracetamol  92.5 2.3 3.7 1.5 
Codeine Opioid 79.3 7.0 9.8 3.9 
Ibuprofen NSAID 77.6 4.2 16.0 2.2 
Amitriptyline TCA 75.9 8.1 7.6 8.4 
Tramadol/Tramacet Opioid 56 17.1 14.3 12.6 
Omeprazole or 
lansoprazole 
Proton pump 
inhibitor 
52.6 10.1 4.4 32.9 
Naproxen NSAID 45.9 45.8 8.3 33.4 
Gabapentin Gabapentinoid 45.6 16.1 11.9 26.5 
Pregabalin Gabapentinoid 36.9 19.9 11.1 32.1 
      
Citalopram SSRI 27.9 15.4 11.0 45.7 
Fluoxetine SSRI 26.2 17.9 24.4 31.4 
Morphine Opioid 22.1 31.2 28.3 18.4 
Duloxetine SNRI 21.5 17.3 9.5 51.7 
Sertraline SSRI 17.6 15.5 11.6 55.3 
Ranitidine Histamine 
antagonist 
16.6 20.1 8.7 54.6 
Steroids Steroid 16.6 30.5 28.6 24.3 
Fentanyl/Butrans 
patches 
Opioid 13.6 24.5 4.7 57.2 
Nortriptyline TCA 9.5 22.9 9.4 58.1 
Audmonal or 
mebeverine 
Smooth muscle 
relaxant 
9.4 12.1 5.5 73.0 
Lidocaine Sodium channel 
blocker 
5.3 27.7 9.2 49.0 
Nefopam Non-opioid 
analgesic 
4.7 18.1 5.0 72.2 
Zolmitriptan Serotonin 
receptor agonist 
1.4 14.1 7.7 64.6 
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Table 3. Participant engagement with non-pharmacological treatments. CBT = cognitive behavioural 
therapy, NA = details not available, TENS = transcutaneous electrical nerve stimulation. * Diet 
change included improved content, gluten-free, paleo, or calorie restricted. 
 
Treatment Class of 
treatment 
Have tried 
this treatment 
% 
Have not tried 
this treatment 
% 
Would not 
try % 
Don’t know 
this treatment 
% 
Heat pad/hot water bottle Physical 
therapies 
81.8 11.2 3.8 3.3 
Walking/running Activity 76.1 7.7 12.7 3.5 
Distraction therapy (hobbies) Alternative 
therapies 
69.6 20.0 5.0 5.4 
Diet change* Diet 54.3 33.8 4.8 7.1 
Vitamin/mineral supplement Diet 53.8 32.7 5.5 8.0 
Swimming Activity 52.4 25.8 17.5 4.2 
Physiotherapy Physical 
therapies 
51.6 38.7 4.9 4.9 
Massage Physical 
therapies 
43.4 41.6 10.3 4.7 
TENS Physical 
therapies 
39.9 41.3 5.7 13.0 
Controlled/graded exercise 
plan 
Activity 39.1 37.5 4.2 19.3 
Meditation/relaxation Psychological 
therapies 
38.2 47.9 6.6 7.3 
Acupuncture Physical 
therapies 
34.9 43.7 13.3 8.1 
CBT Psychological 
therapies 
34.2 39.9 10.4 15.5 
Gym exercise Activity 33.3 21.1 39.5 6.0 
Counselling Psychological 
therapies 
30.6 44.6 11.6 13.2 
Pain management course NA 27.7 54.8 4.6 13.0 
Mindfulness Psychological 
therapies 
25.3 41.6 6.7 26.4 
Cycling Activity 21.7 17.6 55.0 5.7 
Aromatherapy Alternative 
therapies 
21.6 54.4 13.0 11.0 
Hydrotherapy Physical 
therapies 
19.4 57.4 6.0 17.3 
Colpermine Alternative 
therapies 
17.1 31.2 6.4 45.3 
Trigger-point injections Physical 
therapies 
13.1 29.9 10.3 38.0 
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Table 4. Participants’ perspective of the effectiveness and side effects of pharmacological treatments. The effectiveness and side effect scores rated on an 11-
point Likert scale are presented as mean with standard deviation (SD) values for n participants. The patients’ perception of which symptom was most 
effectively reduced and the worst side effect for each treatment are presented as percentage of reporting by participants. IBS = irritable bowel syndrome, 
NSAID = non-steroidal anti-inflammatory drug, SNRI = serotonin noradrenaline reuptake inhibitor, TCA = tricyclic antidepressant. 
 
Drug Class of drug n Effectiveness 
Mean (SD) 
Symptom most effected (%) Side effects 
Mean (SD) 
Worst side effect (%) 
Morphine Opioid 208 6.85 (2.41) Muscular pain (40.8) 5.84 (2.98) Feeling disorientated (30.7) 
Omeprazole or 
lansoprazole 
Proton pump inhibitor 495 6.79 (2.49) IBS/gastric disorders (91.1) 1.73 (2.39) Feeling nauseous (7.4) 
Steroids Steroid 156 5.46 (3.19) Bone/joint pain (32.1) 5.78 (3.34) Weight gain (50.4) 
Ranitidine Histamine antagonist 156 5.43 (2.93) IBS/gastric disorders (89.6) 1.64 (2.61) Feeling nauseous (8.4) 
Sertraline SSRI 167 5.38 (3.04) Depression (70.5) 4.30 (3.27) Feeling tired (14.6) 
Duloxetine SNRI 202 4.97 (2.98) Depression (31.6) 5.24 (3.35) Feeling nauseous (16.1) 
Audmonal or 
mebeverine 
Smooth muscle relaxant 88 4.90 (2.86) IBS/gastric disorders (84.4) 1.87 (2.80) Constipation (8.1); Feeling nauseous (8.1) 
Tramadol/Tramacet Opioid 527 4.89 (3.02) Muscular pain (35.2) 6.20 (3.30) Feeling disorientated (30.4) 
Fluoxetine SSRI 247 4.83 (3.01) Depression (64.8) 5.03 (3.25) Feeling tired (13.9) 
Fentanyl/Butrans 
patches 
Opioid 128 4.61 (2.91) Muscular pain (39) 4.33 (3.37) Feeling disorientated (16.7) 
Citalopram SSRI 262 4.52 (3.18) Depression (63) 4.96 (3.40) Weight gain (12.9) 
Amitriptyline TCA 714 4.38 (3.08) Nerve pain (22.6) 5.89 (3.34) Feeling tired (23.1) 
Naproxen NSAID 432 4.23 (2.79) Muscular pain (44.5) 4.43 (3.45) Feeling nauseous (30.1) 
Pregabalin Gabapentinoid 347 4.22 (3.05) Nerve pain (41) 6.34 (3.22) Feeling disorientated (28.8) 
Nortriptyline TCA 89 4.16 (3.26) Nerve pain (32.1) 5.76 (3.18) Dry mouth (22.1) 
Gabapentin Gabapentinoid 429 4.12 (3.01) Nerve pain (42.8) 6.10 (3.43) Feeling disorientated (24.4) 
Codeine Opioid 746 4.01 (2.65) Muscular pain (39.8) 5.14 (3.12) Feeling nauseous (14.3) 
Lidocaine Sodium channel blocker 44 3.75 (3.70) Muscular pain (28); nerve pain (28) 2.33 (3.16) Made pain worse (12.2) 
Ibuprofen NSAID 730 3.65 (2.61) Muscular pain (50.1) 3.37 (3.53) Feeling nauseous (19.7) 
Zolmitriptan Serotonin receptor 
agonist 
13 3.54 (3.91) Nerve pain (23.1) 5.42 (3.78) Feeling tired (15.4); feeling disorientated (15.4) 
Nefopam Non-opioid analgesic 44 3.35 (3.05) Muscular pain (25); nerve pain (25) 4.97 (3.82) Feeling nauseous (19.5) 
Paracetamol  870 2.54 (2.52) Muscular pain (33.8) 1.17 (2.10) Constipation (7.1) 
Note. Data on dose and speed of titration of dose are not available. 
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Table 5. Participants’ perspective of the effectiveness and side effects of non-pharmacological treatments. The effectiveness and side effect scores rated on an 
11-point Likert scale are presented as mean with standard deviation (SD) values for n participants. The patients’ perception of which symptom was most 
effectively reduced and the worst side effect for each treatment are presented as percentage of reporting by participants. CBT = cognitive behavioural therapy, 
IBS = irritable bowel syndrome, NA = details not available, TENS = transcutaneous electrical nerve stimulation. * diet change included improved content, 
gluten-free, paleo or calorie restricted  
Treatment Class of treatment n Effectiveness 
Mean (SD) 
Worked best for (%) Side effects 
Mean (SD) 
Worst side effect (%) 
Hydrotherapy Physical therapies 183 6.33 (3.01) Muscular pain (58.9) 2.90 (3.08) Feeling tired (39.2) 
Heat pad/hot water 
bottle 
Physical therapies 770 6.08 (2.30) Muscular pain (73.7) 0.63 (1.54) Made pain worse (1.8) 
Massage Physical therapies 408 6.03 (2.96) Muscular pain (77.7) 3.54 (3.44) Painful during treatment (29.9) 
Meditation/relaxation Psychological 
therapies 
359 5.80 (2.56) Anxiety (43.5) 0.62 (1.57) Feeling tired (11.5) 
Mindfulness Psychological 
therapies 
238 5.67 (3.13) Anxiety (33.0) 0.73 (1.86) Feeling tired (7.8) 
Aromatherapy Alternative therapies 203 5.66 (3.02) Muscular pain (34.1) 1.06 (2.19) Feeling tired (8.7) 
Counselling Psychological 
therapies 
288 5.46 (3.17) Depression (48.4) 2.23 (2.91) Worse mood/Anxiety (13.3) 
Diet change* Diet 511 5.44 (2.96) IBS/gastric problems (41.8) 1.79 (2.36) Worse mood (7.5) 
Distraction therapy 
(hobbies) 
Alternative therapies 655 5.36 (2.85) Depression (30.9) 1.94 (2.77) Feeling tired (23.4) 
Colpermine Alternative therapies 161 4.82 (2.94) IBS/gastric disorders (86.1) 1.51 (2.35) Feeling nauseous 8.9 
CBT Psychological 
therapies 
322 4.57 (3.20) Anxiety (34.6) 1.66 (2.68) Anxiety (12.9) 
Acupuncture Physical therapies 328 4.55 (3.52) Muscular pain (40.4) 2.11 (2.90) Painful during treatment (16.3) 
Swimming Activity 493 4.39 (2.93) Muscular pain (42.2) 5.04 (3.28) Made pain worse (37.2) 
Walking/running Activity 716 4.33 (2.91) Depression (21.6) 6.00 (2.98) Made pain worse (50.2) 
Vitamin/mineral 
supplement 
Diet 506 4.19 (2.95) Fatigue (16.1) 0.99 (2.01) Constipation (3.6) 
TENS Physical therapies 375 4.14 (2.97) Muscular pain (47.2) 2.04 (2.94) Made pain worse (13.1) 
Pain management 
course 
NA 261 4.08 (3.04) Muscular pain (21.1) 2.67 (3.20) Feeling tired (15.4) 
Cycling Activity 204 4.03 (2.95) Muscular pain (26.4) 6.13 (3.06) Made pain worse (58.0). 
Gym exercise Activity 313 3.98 (2.86) Muscular pain (29.6) 6.55 (2.85) Made pain worse (59.7) 
Physiotherapy Physical therapies 486 3.59 (3.00) Muscular pain (39.8) 4.94 (3.33) Made pain worse (45.4) 
Controlled/graded 
exercise plan 
Activity 368 3.54 (2.86) Muscular pain (32.0) 5.94 (3.21) Made pain worse (51.8) 
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Table 6. Participants’ perception of acceptability of pharmacological treatments. Acceptability was 
assessed and ranked as a ratio of the mean effective rating relative to the mean side effects rating of 
the treatment presented in Table 3. Ratio of unity is indicated by the solid horizontal line. n = number 
of participants, NSAID = non-steroidal anti-inflammatory, SNRI = serotonin noradrenaline reuptake 
inhibitor, SSRI = selective serotonin reuptake inhibitor, TCA = tricyclic antidepressant. 
 
Drug Class of drug n Acceptability ratio 
Omeprazole or 
lansoprazole 
Proton pump inhibitor 495 3.92 
Ranitidine Histamine antagonist 156 3.31 
Audmonal or 
mebeverine 
Smooth muscle 
relaxant 
88 2.62 
Paracetamol  870 2.17 
Lidocaine Sodium channel 
blocker 
44 1.61 
Sertraline SSRI 167 1.25 
Morphine Opioid 208 1.17 
Ibuprofen NSAID 730 1.08 
Fentanyl/Butrans 
patches 
Opioid 128 1.06 
Fluoxetine SSRI 247 0.96 
Naproxen NSAID 432 0.95 
Duloxetine SNRI 202 0.94 
Steroids Steroids 156 0.94 
Citalopram SSRI 262 0.91 
Tramadol/Tramacet Opioid 527 0.79 
Codeine Opioid 746 0.78 
Amitriptyline TCA 714 0.74 
Nortriptyline TCA 89 0.72 
Gabapentin  Gabapentinoid 429 0.68 
Pregabalin  Gabapentinoid 347 0.67 
Nefopam Non-opioid analgesic 44 0.67 
Zolmitriptan Serotonin receptor 
agonist 
13 0.65 
 
Note. Omeprazole/lansoprazole, ranitidine and audmonal/mebeverine treat gastrointestinal comorbidities. Dose of drugs and 
administration process of lidocaine are not known. 
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Table 7. Participants’ perception of acceptability of non-pharmacological treatments. Acceptability 
was assessed and ranked as a ratio of the mean effective rating relative to the mean side effects rating 
of the treatment presented in Table 6. Ratio of unity is indicated by the solid horizontal line. CBT = 
cognitive behavioural therapy, IBS = irritable bowel syndrome, n = number of participants, NA 
details not available, TENS = transcutaneous electrical nerve stimulation. *Diet change included 
situations such as improved content, gluten-free, paleo or calorie restricted. 
 Class of treatment n Acceptability 
ratio 
Heat pad/hot water bottle Physical therapies 770 9.65 
Meditation/relaxation Psychological therapies 359 9.35 
Mindfulness Psychological therapies 238 7.77 
Aromatherapy Alternative therapies 203 5.33 
Vitamin/mineral 
supplement 
Diet 506 4.23 
Colpermine Alternative therapies 161 3.19 
Diet change* Diet 511 3.03 
Distraction therapy 
(hobbies) 
Alternative therapies 655 2.76 
CBT Psychological therapies 322 2.75 
Counselling Psychological therapies 288 2.45 
Hydrotherapy Physical therapies 183 2.18 
Acupuncture Physical therapies 328 2.15 
TENS  Physical therapies 375 2.03 
Massage Physical therapies 408 1.70 
Pain management course NA 261 1.52 
Swimming Activity 493 0.87 
Physiotherapy Physical therapies 486 0.73 
Walking/running Activity 716 0.72 
Cycling Activity 204 0.65 
Gym exercise Activity 313 0.61 
Controlled/graded 
exercise plan 
Activity 368 0.60 
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